ConductScience.org, home

Paper40147876

Pegylated Liposomal Doxorubicin Combined with Cytarabine and Granulocyte Colony-Stimulating Factor for Treating Newly Diagnosed Older and Unfit Acute Myeloid Leukemia Patients: A Prospective, Single-Center, Single-arm, Phase II Study.

Luo B and 7 others. Technol Cancer Res Treat, 2025. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Pegylated Liposomal Doxorubicin Combined with Cytarabine and Granulocyte Colony-Stimulating Factor for Treating Newly Diagnosed Older and Unfit Acute Myeloid Leukemia Patients: A Prospective, Single-Center, Single-arm, Phase II Study. Papers, record 40147876. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40147876

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Pegylated Liposomal Doxorubicin Combined with Cytarabine and Granulocyte Colony-Stimulating Factor for Treating Newly Diagnosed Older and Unfit Acute Myeloid Leukemia Patients: A Prospective, Single-Center, Single-arm, Phase II Study.
PubMed
Journal
Technol Cancer Res Treat
PubMed
Year
2025
PubMed
Publication types
Journal Article, Clinical Trial, Phase II
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2025-06-02
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Leukemia, Myeloid, AcuteMajor topic
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
Humans
Cytarabine
Female
Male
Aged
Granulocyte Colony-Stimulating Factor
Doxorubicin
Aged, 80 and over
Polyethylene Glycols
Middle Aged
Prospective Studies
Treatment Outcome

Source PubMed

Download CSV of topics

References36

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
135797463Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.Blood2022https://conductscience.org/library/papers/35797463PubMed
230892988Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.J Clin Oncol2019https://conductscience.org/library/papers/30892988PubMed
326139300Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: The GAH Scale.J Geriatr Oncol2015https://conductscience.org/library/papers/26139300PubMed
433604298Maintenance Therapy in AML.Front Oncol2020https://conductscience.org/library/papers/33604298PubMed
52243506Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro.Leukemia1990https://conductscience.org/library/papers/2243506PubMed
611520775Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial.Blood2001https://conductscience.org/library/papers/11520775PubMed
731101526Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges.Blood Rev2019https://conductscience.org/library/papers/31101526PubMed
829339097Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.Lancet Oncol2018https://conductscience.org/library/papers/29339097PubMed
921828126A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia.Blood2011https://conductscience.org/library/papers/21828126PubMed
1035917453Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy.Blood2022https://conductscience.org/library/papers/35917453PubMed
1122082134A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome.J Hematol Oncol2011https://conductscience.org/library/papers/22082134PubMed
1238539418Venetoclax Plus Azacitidine as a Bridge Treatment to Allogeneic Stem Cell Transplantation in Unfit Patients with Acute Myeloid Leukemia.Cancers (Basel)2024https://conductscience.org/library/papers/38539418PubMed
1330024784CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.J Clin Oncol2018https://conductscience.org/library/papers/30024784PubMed
1415994282Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.Blood2005https://conductscience.org/library/papers/15994282PubMed
1525987659International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.Blood2015https://conductscience.org/library/papers/25987659PubMed
1620668231Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia.Blood2010https://conductscience.org/library/papers/20668231PubMed
1737363050A phase II trial of decitabine, bortezomib and pegylated liposomal doxorubicin for the treatment of relapsed or refractory AML.Leuk Res Rep2023https://conductscience.org/library/papers/37363050PubMed
1830630862Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients.Blood2019https://conductscience.org/library/papers/30630862PubMed
1929017371Cytarabine and daunorubicin for the treatment of acute myeloid leukemia.Expert Opin Pharmacother2017https://conductscience.org/library/papers/29017371PubMed
2014673054
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.
J Clin Oncol2003https://conductscience.org/library/papers/14673054PubMed

See all 36 referencesDownload CSV of references

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
CSF31440PubTator's text mininghttps://conductscience.org/library/genes/1440

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40147876

GET https://conductscience.org/api/papers/v1/40147876/references?page=2